GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

The new multi-purpose facility will be able to produce sterile liquid vaccines and medicines and will also include an R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK intends to establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. The planned expansion will double the size and capacity of the Marietta site.

Regis Simard, president Global Supply Chain, GSK, said: This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next-generation medicines and vaccines to people around the world. We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site.”

Construction of the new facilities is expected to start by the end of this year. According to GSK, the drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028.

© GSK
© GSK

Company

GlaxoSmithKline UK Ltd.

980 Great West Road
Brentford, TW8 9GS
UK

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.